Shares in Senseonics (NYSE:SENS) fell slightly today after the diabetes-focused device maker posted fourth quarter and full year 2018 earnings that beat loss-per-share consensus but missed sales expectations and lowered its guidance for the 2019 fiscal year. The Germantown, Md.-based company posted losses of $7.3 million, or 4¢ per share, on sales of $7.2 million for […]
HydroCision names Tranchemontagne as CEO | Personnel Moves – March 12, 2019
HydroCision said early this month that it tapped former Smith & Nephew (NYSE:SNN) exec Alain Tranchemontagne as its new chief executive officer. Prior to joining Boston-based HydroCision, Tranchemontagne held a position as U.S. business commercial development senior VP at Smith & Nephew. Before joining Smith & Nephew, Tranchemontagne also held positions at Covidien in senior marketing roles […]
Senseonics inks CGM data deal with Glooko
Senseonics (NYSE:SENS) said today that data from its Eversense continuous glucose monitoring system can be integrated into Glooko‘s diabetes data management tech. Thanks to the new partnership, Eversense users will be able to view historical glucose trends in Glooko’s mobile and web apps as well as real-time data from the Eversense mobile app, according to Senseonics. Get […]
Senseonics partners to provide veterans with Eversense CGM
Senseonics (NYSE:SENS) this week announced that it partnered with Geo-Med to provide access to the Eversense continuous glucose monitor to more than 9 million veterans and U.S. government staff. The company’s Eversense device is the first CGM system to feature an implantable sensor that can be worn for up to 90 days. Get the full story […]
Senseonics extends distribution agreement with Roche Diabetes Care
Senseonics Holdings (NYSE-American: SENS) — maker of an implantable continuous glucose monitoring system for people with diabetes — has extended its distribution agreement with Roche Diabetes Care. The agreement extension, announced yesterday, has Roche continuing as Senseonics’ exclusive distributor in Europe, the Middle East and Africa — excluding Scandinavia and Israel. The agreement also adds 17 […]
Senseonics wins MRI-safe FDA nod for Eversense CGM
Senseonics announced that it has received notice from the FDA that its Eversense sensor no longer has to be removed for MRI scanning. “Based on our testing, we have demonstrated hat it is safe for patients to leave the Eversense Sensor in place, even when they need to have an MRI,” Tim Goodnow, president and […]
Insulet taps former Medtronic finance exec McMillan as CFO | Personnel Moves – January 8, 2019
Insulet (NSDQ:PODD) said yesterday that it tapped former Medtronic minimally invasive therapies CFO and finance VP Wayde McMillan as its new chief financial officer, replacing Michael Levitz. The Acton, Mass.-based diabetes-focused medtech company said that McMillan will join the company in February and that Levitz will continue as an advisor for a period following the […]
Senseonics touts first U.S. trial implant of 180-day CGM
Senseonics (NYSE:SENS) said yesterday that its Eversense XL 180-day continuous glucose sensor was implanted into the first participant of a trial designed to support a pre-market application to the FDA. The company’s 180-patient Promise trial is slated to study the safety and efficacy of the Eversense device in people with diabetes over 180 days. Get the […]
Senseonics CFO Elsey to retire | Personnel Moves – December 4, 2018
Senseonics (NYSE:SENS) said yesterday that its CFO R. Elsey is retiring for the company, and that it has begun searching for a permanent replacement. The Germantown, Md.-based company said that Elsey will stay on until a replacement is appointed, and remain on in an advisory role through to the completion of the company’s 2018 fiscal […]
Senseonics reports mixed Q3 results
Shares in Senseonics (NYSE:SENS) fell today after the medical device maker missed EPS expectations but met sales estimates on Wall Street with its third quarter financial results. The Germantown, Md.-based company posted a net loss of -$31.9 million on sales of $5.2 million for the 3 months ended Sept. 30. Quarterly net losses were up 83% on sales […]
Senseonics wins another FDA approval for its implantable CGM
Senseonics (NYSE:SENS) said this week that it won another FDA approval for its implantable continuous glucose monitoring system, giving nurse practitioners and physicians assistants the ability to implant and remove the Eversense device. When the product was first approved by the FDA in June, only trained physicians were allowed to conduct the sensor insertion and removal procedures. Get […]
- 1
- 2
- 3
- …
- 5
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
YouTube